Search

Your search keyword '"de Bruijne, Joep"' showing total 128 results
Start Over Author "de Bruijne, Joep"
128 results on '"de Bruijne, Joep"'

1. Holmium-166 radioembolisation dosimetry in HCC

Author

Reinders, Margot T. M., Braat, Arthur J. A. T., van Erpecum, Karel J., de Bruijne, Joep, Bruijnen, Rutger C. G., Sprengers, Dave, de Man, Rob, Vegt, Erik, IJzermans, Jan N. M., Elias, Sjoerd G., Lam, Marnix G. E. H., and Smits, Maarten L. J.

Published
2024
Full Text
View/download PDF

3. Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol

Author

Andel, Daan, Lam, Marnix G. E. H., de Bruijne, Joep, Smits, Maarten L. J., Braat, Arthur J. A. T., Moelker, Adriaan, Vegt, Erik, Ruiter, Simeon J. S., Noordzij, Walter, Grazi, Gianluca, Vallati, Giulio E., Bennink, Roel J., van Delden, Otto M., Kranenburg, Onno W., Ijzermans, Jan N. M., Nijkamp, Maarten W., Erdmann, Joris I., Sciuto, Rosa, Hagendoorn, Jeroen, and Borel Rinkes, Inne H. M.

Published
2023
Full Text
View/download PDF

5. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

Author

Patmore, Lesley A., van Eekhout, Kirsi M.A., Buti, Maria, Koc, Özgur.M., Agarwal, Kosh, de Knegt, Rob J., Janssen, Harry L.A., van der Valk, Marc, Lieveld, Faydra I., Hansen, Bettina E., Kramer, Matthijs, de Bruijne, Joep, Claassen, Mark A.A., Smit, Colette, de Man, Rob A., Takkenberg, Bart, Carey, Ivana, and Sonneveld, Milan J.

Published
2024
Full Text
View/download PDF

6. TOP-401-YI Improvement of liver stiffness during nucleo (s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk

Author

Patmore, Lesley A., primary, Liang, Yan, additional, Kilany, Mai, additional, d'Almeida, Arno Furquim, additional, Wong, Vincent Wai-Sun, additional, Vanwolleghem, Thomas, additional, Honkoop, Pieter, additional, Blokzijl, Hans, additional, Koc, Ozgur, additional, Janssen, Harry L.A., additional, Kramer, Matthijs, additional, de Bruijne, Joep, additional, Kaewdech, A., additional, de Man, Robert A., additional, Takkenberg, R. Bart, additional, Wong, Grace Lai-Hung, additional, Feld, Jordan J., additional, and Sonneveld, Milan J., additional

Published
2024
Full Text
View/download PDF

8. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

Author

UMC Utrecht Holding, Unit Opleiding Aios, MS MDL 1, Patmore, Lesley A., van Eekhout, Kirsi M.A., Buti, Maria, Koc, Özgur M., Agarwal, Kosh, de Knegt, Rob J., Janssen, Harry L.A., van der Valk, Marc, Lieveld, Faydra I., Hansen, Bettina E., Kramer, Matthijs, de Bruijne, Joep, Claassen, Mark A.A., Smit, Colette, de Man, Rob A., Takkenberg, Bart, Carey, Ivana, Sonneveld, Milan J., the HARP study group and HepNed, UMC Utrecht Holding, Unit Opleiding Aios, MS MDL 1, Patmore, Lesley A., van Eekhout, Kirsi M.A., Buti, Maria, Koc, Özgur M., Agarwal, Kosh, de Knegt, Rob J., Janssen, Harry L.A., van der Valk, Marc, Lieveld, Faydra I., Hansen, Bettina E., Kramer, Matthijs, de Bruijne, Joep, Claassen, Mark A.A., Smit, Colette, de Man, Rob A., Takkenberg, Bart, Carey, Ivana, Sonneveld, Milan J., and the HARP study group and HepNed

Published
2024

9. Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA): A Comparative Analysis

Author

MS Radiologie, Other research (not in main researchprogram), Circulatory Health, Fysica Radiologie, Brain, Cancer, MS MDL 1, MS Radiotherapie, MS CGO, Wijnen, Niek, Bruijnen, Rutger C G, Vonken, Evert-Jan P A, de Jong, Hugo W A M, de Bruijne, Joep, Bol, Guus M, Hagendoorn, Jeroen, Intven, Martijn P W, Smits, Maarten L J, MS Radiologie, Other research (not in main researchprogram), Circulatory Health, Fysica Radiologie, Brain, Cancer, MS MDL 1, MS Radiotherapie, MS CGO, Wijnen, Niek, Bruijnen, Rutger C G, Vonken, Evert-Jan P A, de Jong, Hugo W A M, de Bruijne, Joep, Bol, Guus M, Hagendoorn, Jeroen, Intven, Martijn P W, and Smits, Maarten L J

Published
2024

10. 90Y-/166Ho- ‘Radiation lobectomy’ for liver tumors induces abnormal morphology and impaired drainage of peritumor lymphatics

Author

Heelkundig Oncologische Disciplines, Lab Translational Oncology, Cancer, Researchgr. Nucleaire Geneeskunde, MS Radiologie, MS CGO, MS MDL 1, Pathologie Pathologen staf, Regenerative Medicine and Stem Cells, Andel, Daan, van den Bent, Lotte, Lam, Marnix, Smits, Maarten, Molenaar, Isaac Quintus, de Bruijne, Joep, Laclé, Miangela Marie, Kranenburg, Onno, Borel Rinkes, Inne, Hagendoorn, Jeroen, Heelkundig Oncologische Disciplines, Lab Translational Oncology, Cancer, Researchgr. Nucleaire Geneeskunde, MS Radiologie, MS CGO, MS MDL 1, Pathologie Pathologen staf, Regenerative Medicine and Stem Cells, Andel, Daan, van den Bent, Lotte, Lam, Marnix, Smits, Maarten, Molenaar, Isaac Quintus, de Bruijne, Joep, Laclé, Miangela Marie, Kranenburg, Onno, Borel Rinkes, Inne, and Hagendoorn, Jeroen

Published
2024

11. Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature

Author

Braat, Manon N. G. J. A., primary, Ebbers, Sander C., additional, Alsultan, Ahmed A., additional, Neek, Atal O., additional, Bruijnen, Rutger C. G., additional, Smits, Maarten L. J., additional, de Bruijne, Joep, additional, Lam, Marnix G. E. H., additional, and Braat, Arthur J. A. T., additional

Published
2023
Full Text
View/download PDF

12. Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA): A Comparative Analysis.

Author

Wijnen, Niek, Bruijnen, Rutger C. G., Vonken, Evert-Jan P. A., de Jong, Hugo W. A. M., de Bruijne, Joep, Bol, Guus M., Hagendoorn, Jeroen, Intven, Martijn P. W., and Smits, Maarten L. J.

Subjects
LIVER tumors, HEPATIC artery, ABLATION techniques, CANCER relapse, COMPUTED tomography, RADIO frequency therapy, TREATMENT effectiveness, RETROSPECTIVE studies, COLORECTAL cancer, DESCRIPTIVE statistics, LONGITUDINAL method, METASTASIS, KAPLAN-Meier estimator, LOG-rank test, MICROWAVES, CATHETER ablation, PROGRESSION-free survival, COMPARATIVE studies
Abstract

Simple Summary: Catheter-assisted ablations have shown significant improvements in the outcomes of percutaneous thermal ablation for liver cancer. A novel approach within this category is the Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) technique, which integrates C-arm CT hepatic arteriography with C-arm guided navigation. This cohort study aimed to assess the effectiveness and safety of the HepACAGA technique compared to conventional ultrasound/CT-guided thermal ablation in treating hepatocellular carcinoma and colorectal liver metastasis. A total of 68 patients with 120 tumors undergoing HepACAGA and 53 patients with 78 tumors undergoing conventional ablation were included. The HepACAGA technique demonstrated superior outcomes: lower rates of local tumor recurrence, longer local tumor recurrence-free survival, and fewer procedure-related complications. These findings suggest that HepACAGA is a safer and more effective ablation technique in liver cancer treatment compared to conventional ablation methods. Purpose: Hepatic Arteriography and C-Arm CT-Guided Ablation of liver tumors (HepACAGA) is a novel technique, combining hepatic–arterial contrast injection with C-arm CT-guided navigation. This study compared the outcomes of the HepACAGA technique with patients treated with conventional ultrasound (US) and/or CT-guided ablation. Materials and Methods: In this retrospective cohort study, all consecutive patients with hepatocellular carcinoma (HCC) or colorectal liver metastases (CRLM) treated with conventional US-/CT-guided ablation between 1 January 2015, and 31 December 2020, and patients treated with HepACAGA between 1 January 2021, and 31 October 2023, were included. The primary outcome was local tumor recurrence-free survival (LTRFS). Secondary outcomes included the local tumor recurrence (LTR) rate and complication rate. Results: 68 patients (120 tumors) were included in the HepACAGA cohort and 53 patients (78 tumors) were included in the conventional cohort. In both cohorts, HCC was the predominant tumor type (63% and 73%, respectively). In the HepACAGA cohort, all patients received microwave ablation. Radiofrequency ablation was the main ablation technique in the conventional group (78%). LTRFS was significantly longer for patients treated with the HepACAGA technique (p = 0.015). Both LTR and the complication rate were significantly lower in the HepACAGA cohort compared to the conventional cohort (LTR 5% vs. 26%, respectively; p < 0.001) (complication rate 4% vs. 15%, respectively; p = 0.041). Conclusions: In this study, the HepACAGA technique was safer and more effective than conventional ablation for HCC and CRLM, resulting in lower rates of local tumor recurrence, longer local tumor recurrence-free survival and fewer procedure-related complications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC:the RALLY protocol

Author

Andel, Daan, Lam, Marnix G.E.H., de Bruijne, Joep, Smits, Maarten L.J., Braat, Arthur J.A.T., Moelker, Adriaan, Vegt, Erik, Ruiter, Simeon J.S., Noordzij, Walter, Grazi, Gianluca, Vallati, Giulio E., Bennink, Roel J., van Delden, Otto M., Kranenburg, Onno W., Ijzermans, Jan N.M., Nijkamp, Maarten W., Erdmann, Joris I., Sciuto, Rosa, Hagendoorn, Jeroen, Borel Rinkes, Inne H.M., Andel, Daan, Lam, Marnix G.E.H., de Bruijne, Joep, Smits, Maarten L.J., Braat, Arthur J.A.T., Moelker, Adriaan, Vegt, Erik, Ruiter, Simeon J.S., Noordzij, Walter, Grazi, Gianluca, Vallati, Giulio E., Bennink, Roel J., van Delden, Otto M., Kranenburg, Onno W., Ijzermans, Jan N.M., Nijkamp, Maarten W., Erdmann, Joris I., Sciuto, Rosa, Hagendoorn, Jeroen, and Borel Rinkes, Inne H.M.

Abstract

Background: High dose unilobar radioembolization (also termed ‘radiation lobectomy’)—the transarterial unilobar infusion of radioactive microspheres as a means of controlling tumour growth while concomitantly inducing future liver remnant hypertrophy—has recently gained interest as induction strategy for surgical resection. Prospective studies on the safety and efficacy of the unilobar radioembolization-surgery treatment algorithm are lacking. The RALLY study aims to assess the safety and toxicity profile of holmium-166 unilobar radioembolization in patients with hepatocellular carcinoma ineligible for surgery due to insufficiency of the future liver remnant. Methods: The RALLY study is a multicenter, interventional, non-randomized, open-label, non-comparative safety study. Patients with hepatocellular carcinoma who are considered ineligible for surgery due to insufficiency of the future liver remnant (< 2.7%/min/m2 on hepatobiliary iminodiacetic acid scan will be included. A classical 3 + 3 dose escalation model will be used, enrolling three to six patients in each cohort. The primary objective is to determine the maximum tolerated treated non-tumourous liver-absorbed dose (cohorts of 50, 60, 70 and 80 Gy). Secondary objectives are to evaluate dose–response relationships, to establish the safety and feasibility of surgical resection following unilobar radioembolization, to assess quality of life, and to generate a biobank. Discussion: This will be the first clinical study to assess the unilobar radioembolization-surgery treatment algorithm and may serve as a stepping stone towards its implementation in routine clinical practice. Trial registration: Netherlands Trial Register NL8902 , registered on 2020–09-15.

Published
2023

15. Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature

Author

Cancer, MS Radiologie, Researchgr. Nucleaire Geneeskunde, Other research (not in main researchprogram), MS MDL 1, Braat, Manon N G J A, Ebbers, Sander C, Alsultan, Ahmed A, Neek, Atal O, Bruijnen, Rutger C G, Smits, Maarten L J, de Bruijne, Joep, Lam, Marnix G E H, Braat, Arthur J A T, Cancer, MS Radiologie, Researchgr. Nucleaire Geneeskunde, Other research (not in main researchprogram), MS MDL 1, Braat, Manon N G J A, Ebbers, Sander C, Alsultan, Ahmed A, Neek, Atal O, Bruijnen, Rutger C G, Smits, Maarten L J, de Bruijne, Joep, Lam, Marnix G E H, and Braat, Arthur J A T

Published
2023

16. Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation

Author

MS Radiologie, Cancer, Other research (not in main researchprogram), Researchgr. Systems Radiology, Circulatory Health, MCS-team, MS CGO, MS MDL 1, Smits, Maarten L.J., Bruijnen, Rutger C.G., Tetteroo, Philip, Vonken, Evert jan P.A., Meijerink, Martijn R., Hagendoorn, Jeroen, de Bruijne, Joep, Prevoo, Warner, MS Radiologie, Cancer, Other research (not in main researchprogram), Researchgr. Systems Radiology, Circulatory Health, MCS-team, MS CGO, MS MDL 1, Smits, Maarten L.J., Bruijnen, Rutger C.G., Tetteroo, Philip, Vonken, Evert jan P.A., Meijerink, Martijn R., Hagendoorn, Jeroen, de Bruijne, Joep, and Prevoo, Warner

Published
2023

17. Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol

Author

MS HOD, Lab Translational Oncology, Researchgr. Nucleaire Geneeskunde, Cancer, MS MDL 1, MS Radiologie, Regenerative Medicine and Stem Cells, MS CGO, Andel, Daan, Lam, Marnix G.E.H., de Bruijne, Joep, Smits, Maarten L.J., Braat, Arthur J.A.T., Moelker, Adriaan, Vegt, Erik, Ruiter, Simeon J.S., Noordzij, Walter, Grazi, Gianluca, Vallati, Giulio E., Bennink, Roel J., van Delden, Otto M., Kranenburg, Onno W., Ijzermans, Jan N.M., Nijkamp, Maarten W., Erdmann, Joris I., Sciuto, Rosa, Hagendoorn, Jeroen, Borel Rinkes, Inne H.M., MS HOD, Lab Translational Oncology, Researchgr. Nucleaire Geneeskunde, Cancer, MS MDL 1, MS Radiologie, Regenerative Medicine and Stem Cells, MS CGO, Andel, Daan, Lam, Marnix G.E.H., de Bruijne, Joep, Smits, Maarten L.J., Braat, Arthur J.A.T., Moelker, Adriaan, Vegt, Erik, Ruiter, Simeon J.S., Noordzij, Walter, Grazi, Gianluca, Vallati, Giulio E., Bennink, Roel J., van Delden, Otto M., Kranenburg, Onno W., Ijzermans, Jan N.M., Nijkamp, Maarten W., Erdmann, Joris I., Sciuto, Rosa, Hagendoorn, Jeroen, and Borel Rinkes, Inne H.M.

Published
2023

18. Hepatocellular Carcinoma Risk in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B Living in Europe: An International Multicenter Retrospective Cohort Study

Author

Patmore, Lesley, primary, van Eekhout, Kirsi, additional, Buti, Maria, additional, Koc, Ozgur, additional, Agarwal, Kosh, additional, de Knegt, Robert J., additional, Janssen, Harry, additional, van der Valk, Marc, additional, Lieveld, Faydra, additional, Kramer, Matthijs, additional, de Bruijne, Joep, additional, Claassen, Mark, additional, Smit, Colette, additional, de Man, Rob, additional, Takkenberg, R. Bart, additional, Carey, Ivana, additional, Sonneveld, Milan, additional, and Group, HARP Study, additional

Published
2023
Full Text
View/download PDF

20. Nutritional status in patients with hepatocellular carcinoma: Potential relevance for clinical outcome

Author

Afdeling Dietetiek, MS Hoofd-Hals Chirurgische Oncologie, VS-DIGD, MS MDL 1, Cancer, Infection & Immunity, van Dijk, Anne M, Coppens, Bart J P, van Beers, Maartje A, Bruins Slot, Alexandra S, Verstraete, Carina J R, de Bruijne, Joep, Vleggaar, Frank P, van Erpecum, Karel J, Afdeling Dietetiek, MS Hoofd-Hals Chirurgische Oncologie, VS-DIGD, MS MDL 1, Cancer, Infection & Immunity, van Dijk, Anne M, Coppens, Bart J P, van Beers, Maartje A, Bruins Slot, Alexandra S, Verstraete, Carina J R, de Bruijne, Joep, Vleggaar, Frank P, and van Erpecum, Karel J

Published
2022

21. Systematic review with meta‐analysis: Branched‐chain amino acid supplementation in liver disease.

Author

van Dijk, Anne M., Bruins Slot, Alexandra S., Portincasa, Piero, Siegerink, Sebastiaan N., Chargi, Najiba, Verstraete, Carina J. R., de Bruijne, Joep, Vleggaar, Frank P., and van Erpecum, Karel J.

Subjects
BRANCHED chain amino acids, LIVER diseases, PARACENTESIS, AMINO acids, DIETARY supplements, ESOPHAGEAL varices, NUTRITIONAL status
Abstract

Background: Dietary supplementation with branched‐chain amino acids (BCAA) is often used in cirrhotic patients to improve nutritional status. We wanted to explore the evidence for BCAA supplementation in chronic liver disease. Methods: We searched MEDLINE and EMBASE for studies with BCAA supplementation with the presence of a disease‐control group (placebo or no intervention) using search terms 'liver cirrhosis', 'hepatocellular carcinoma', 'branched chain amino acids' and relevant synonyms. Risk of bias was assessed using ROBINS‐I and RoB 2.0 tools. Meta‐analyses were performed with a random‐effects model. Results were reported following EQUATOR guidelines. Results: Of 3378 studies screened by title and abstract, 54 were included (34 randomized controlled trials, 5 prospective case–control studies, 13 retrospective case–control studies: in total 2308 patients BCAA supplementation, 2876 disease‐controls). Risk of bias was high/serious for almost all studies. According to meta‐analyses, long‐term (at least 6 months) BCAA supplementation in cirrhotic patients significantly improved event‐free survival (p =.008; RR.61 95% CI.42–.88) and tended to improve overall survival (p =.05; RR.58 95% CI.34–1.00). Two retrospective studies suggested the beneficial effects during sorafenib for hepatocellular carcinoma. Available studies reported no beneficial effects or contradictory results of BCAA after other specific therapeutic interventions (resection or radiological interventions for hepatocellular carcinoma, liver transplantation, paracentesis or variceal ligation). No convincing beneficial effects of BCAA supplementation on liver function, nutritional status or quality of life were found. No study reported serious side effects of BCAA. Conclusions: Prophylactic BCAA supplementation appears safe and might improve survival in cirrhotic patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection

Author

MS MDL 1, Mulder, Midas B., de Man, Robert A., Kamar, Nassim, Durmaz, Gűlcan, de Bruijne, Joep, Vanwolleghem, Thomas, Izopet, Jacques, Gandia, Peggy, van der Eijk, Annemiek A., van Gelder, Teun, Hesselink, Dennis A., de Winter, Brenda C.M., MS MDL 1, Mulder, Midas B., de Man, Robert A., Kamar, Nassim, Durmaz, Gűlcan, de Bruijne, Joep, Vanwolleghem, Thomas, Izopet, Jacques, Gandia, Peggy, van der Eijk, Annemiek A., van Gelder, Teun, Hesselink, Dennis A., and de Winter, Brenda C.M.

Published
2021

31. Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection

Author

Mulder, Midas B., primary, de Man, Robert A., additional, Kamar, Nassim, additional, Durmaz, Gűlcan, additional, de Bruijne, Joep, additional, Vanwolleghem, Thomas, additional, Izopet, Jacques, additional, Gandia, Peggy, additional, van der Eijk, Annemiek A., additional, van Gelder, Teun, additional, Hesselink, Dennis A., additional, and de Winter, Brenda C.M., additional

Published
2020
Full Text
View/download PDF

35. Adherence to ursodeoxycholic acid therapy in patients with cholestatic and autoimmune liver disease

Author

MS MDL 1, Onderzoek, MS Interne Geneeskunde, Infection & Immunity, Cancer, Leoni, Maria Cristina, Amelung, Linde, Lieveld, Faydra I., van den Brink, Janneke, de Bruijne, Joep, Arends, Joop E., van Erpecum, Carel Peter, van Erpecum, Karel J., MS MDL 1, Onderzoek, MS Interne Geneeskunde, Infection & Immunity, Cancer, Leoni, Maria Cristina, Amelung, Linde, Lieveld, Faydra I., van den Brink, Janneke, de Bruijne, Joep, Arends, Joop E., van Erpecum, Carel Peter, and van Erpecum, Karel J.

Published
2019

37. The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes : A Dutch Prospective Cohort Study

Author

Kracht, Patricia A.M., Lieveld, Faydra I., Amelung, Linde M., Verstraete, Carina J.R., Mauser-Bunschoten, Eveline P., de Bruijne, Joep, Siersema, Peter D., Hoepelman, Andy I.M., Arends, Joop E., van Erpecum, Karel J., Kracht, Patricia A.M., Lieveld, Faydra I., Amelung, Linde M., Verstraete, Carina J.R., Mauser-Bunschoten, Eveline P., de Bruijne, Joep, Siersema, Peter D., Hoepelman, Andy I.M., Arends, Joop E., and van Erpecum, Karel J.

Published
2018

38. The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study

Author

MS Infectieziekten, MS MDL 1, Functieafdeling, Poli Van Creveldkliniek Medisch, Circulatory Health, Infection & Immunity, MS Interne Geneeskunde, Cancer, Kracht, Patricia A.M., Lieveld, Faydra I., Amelung, Linde M., Verstraete, Carina J.R., Mauser-Bunschoten, Eveline P., de Bruijne, Joep, Siersema, Peter D., Hoepelman, Andy I.M., Arends, Joop E., van Erpecum, Karel J., MS Infectieziekten, MS MDL 1, Functieafdeling, Poli Van Creveldkliniek Medisch, Circulatory Health, Infection & Immunity, MS Interne Geneeskunde, Cancer, Kracht, Patricia A.M., Lieveld, Faydra I., Amelung, Linde M., Verstraete, Carina J.R., Mauser-Bunschoten, Eveline P., de Bruijne, Joep, Siersema, Peter D., Hoepelman, Andy I.M., Arends, Joop E., and van Erpecum, Karel J.

Published
2018

39. Nieuwe klasse medicijnen voor chronische hepatitis C

Author

Aronson, Sem J., de Bruijne, Joep, Schinkel, Janke, Weegink, Christine J., van der Valk, Marc, Reesink, Hendrik W., Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Amsterdam institute for Infection and Immunity, Medical Microbiology and Infection Prevention, and Infectious diseases

Subjects
virus diseases
Abstract

Worldwide approximately 130-210 million people suffer from chronic hepatitis C. Adequate antiviral therapy reduces morbidity and mortality caused by chronic hepatitis C and prevents further spread of the hepatitis C-virus (HCV). The current standard treatment of chronic hepatitis C, consisting of the combination of pegylated interferon-α (peginterferon) and ribavirin, lasts 24-48 weeks, and is accompanied by significant side effects and has a suboptimal chance of success. Protease inhibitors, which have recently been registered, belong to a new class of medicines which directly affect the life cycle of HCV. Protease inhibitors, in combination with peginterferon and ribavirin, provide almost double the chance of curing in patients with HCV genotype 1. Treatment duration can be shortened in a considerable proportion of these patients. Since treatment with protease inhibitors can lead to resistant virus strains and this therapy leads to additional side effects, the complexity of treatment will increase

Published
2012

41. Reply from the authors

Author

Dik, Kathelijne, primary, de Bruijne, Joep, additional, Takkenberg, R. Bart, additional, Roelofs, Joris J., additional, Tempelmans, Marjan J., additional, Dijkgraaf, Marcel G. W., additional, Gelderblom, Huub C., additional, Reesink, Henk W., additional, Meijers, Joost C. M., additional, Jansen, Peter L., additional, and Levi, Marcel, additional

Published
2012
Full Text
View/download PDF

42. Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir

Author

Thomas, Xiomara V., primary, de Bruijne, Joep, additional, Sullivan, James C., additional, Kieffer, Tara L., additional, Ho, Cynthia K. Y., additional, Rebers, Sjoerd P., additional, de Vries, Michel, additional, Reesink, Hendrik W., additional, Weegink, Christine J., additional, Molenkamp, Richard, additional, and Schinkel, Janke, additional

Published
2012
Full Text
View/download PDF

43. Rapid Decline of Viral RNA in Chronic Hepatitis C Patients Treated Once Daily with IDX320: A Novel Macrocyclic HCV Protease Inhibitor

Author

de Bruijne, Joep, primary, van Vliet, Andre, additional, Weegink, Christine J, additional, Mazur, Włodzimierz, additional, Wiercinska-Drapało, Alicja, additional, Simon, Krzysztof, additional, Cholewińska-Szymańska, Grażyna, additional, Kapocsi, Judit, additional, Várkonyi, István, additional, Zhou, Xiao-Jian, additional, Temam, Marie-Francoise, additional, Molles, Jeffrey, additional, Chen, Jie, additional, Pietropaolo, Keith, additional, McCarville, Joseph F, additional, Sullivan-Bólyai, John Z, additional, Mayers, Douglas, additional, and Reesink, Hendrik, additional

Published
2012
Full Text
View/download PDF

44. Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design

Author

Hotho, Daphne M, primary, de Bruijne, Joep, additional, O'Farrell, A Marie, additional, Boyea, Teresa, additional, Li, Jianke, additional, Bracken, Michele, additional, Li, Xin, additional, Campbell, David, additional, Guler, Hans-Peter, additional, Weegink, Christine J, additional, Schinkel, Janke, additional, Molenkamp, Richard, additional, van de Wetering de Rooij, Jeroen, additional, van Vliet, Andre, additional, Janssen, Harry LA, additional, de Knegt, Robert J, additional, and Reesink, Hendrik W, additional

Published
2012
Full Text
View/download PDF

47. Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7

Author

Boonstra, Andre, primary, Liu, Bi-Sheng, additional, Groothuismink, Zwier MA, additional, Bergmann, Jilling F, additional, de Bruijne, Joep, additional, Hotho, Daphne M, additional, Hansen, Bettina E, additional, van Vliet, Andre A, additional, van de Wetering de Rooij, Jeroen, additional, Fletcher, Simon P, additional, Bauman, Lisa A, additional, Rahimy, Mohamad, additional, Appleman, James R, additional, Freddo, James L, additional, Reesink, Hendrik W, additional, de Knegt, Robert J, additional, and Janssen, Harry LA, additional

Published
2011
Full Text
View/download PDF

48. Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor

Author

de Bruijne, Joep, primary, Bergmann, Jilling F, additional, Weegink, Christine J, additional, van Nieuwkerk, Carin MJ, additional, de Knegt, Robert J, additional, Komoda, Yasumasa, additional, van de Wetering de Rooij, Jeroen J, additional, van Vliet, Andre, additional, Jansen, Peter LM, additional, Molenkamp, Richard, additional, Schinkel, Janke, additional, Reesink, Hendrik, additional, and Janssen, Harry LA, additional

Published
2010
Full Text
View/download PDF

50. Micrornas: Role and Therapeutic Targets in Viral Hepatitis

Author

van der Ree, Meike H, de Bruijne, Joep, Kootstra, Neeltje A, Jansen, Peter LM, and Reesink, Hendrik W

Abstract

MicroRNAs regulate gene expression by binding to the 3‘-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. Micro-RNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. MicroRNA-122 is also an important host factor for the HCV and promotes HCV replication. In contrast to HCV, microRNA-122 inhibits replication of the HBV. MicroRNA-122 acts as a tumour suppressor and reduced levels of microRNA-122 are associated with hepatocellular carcinoma. MicroRNAs other than microRNA-122 have been linked to viral hepatitis, fibrosis and inflammation. In this review, we discuss function and clinical implications of microRNA-122 and other microRNAs in liver diseases, especially viral hepatitis.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results